The Shift Toward US Pharmaceutical Manufacturing

Considerations in attaining the right global mix

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72 percent of facilities manufacturing APIs for American drugs are overseas, with 13 percent in China.¹ Here, we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how Curia assures the continual production of urgently needed drugs.